Abeona Therapeutics (ABEO) Competitors $5.54 +0.29 (+5.52%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$5.52 -0.03 (-0.45%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABEO vs. PRAX, NUVB, COLL, WVE, ORIC, TRVI, PGEN, IMNM, CRON, and BGMShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Praxis Precision Medicines (PRAX), Nuvation Bio (NUVB), Collegium Pharmaceutical (COLL), WAVE Life Sciences (WVE), Oric Pharmaceuticals (ORIC), Trevi Therapeutics (TRVI), Precigen (PGEN), Immunome (IMNM), Cronos Group (CRON), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry. Abeona Therapeutics vs. Its Competitors Praxis Precision Medicines Nuvation Bio Collegium Pharmaceutical WAVE Life Sciences Oric Pharmaceuticals Trevi Therapeutics Precigen Immunome Cronos Group BGM Group Praxis Precision Medicines (NASDAQ:PRAX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment. Does the media favor PRAX or ABEO? In the previous week, Praxis Precision Medicines and Praxis Precision Medicines both had 4 articles in the media. Praxis Precision Medicines' average media sentiment score of 0.61 beat Abeona Therapeutics' score of 0.20 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PRAX or ABEO more profitable? Abeona Therapeutics' return on equity of 89.05% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Praxis Precision MedicinesN/A -60.07% -54.84% Abeona Therapeutics N/A 89.05%45.64% Which has better valuation and earnings, PRAX or ABEO? Abeona Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPraxis Precision Medicines$8.55M133.66-$182.82M-$12.29-4.42Abeona Therapeutics$3.50M81.17-$63.73M$0.707.91 Which has more volatility and risk, PRAX or ABEO? Praxis Precision Medicines has a beta of 2.62, suggesting that its stock price is 162% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Do analysts rate PRAX or ABEO? Praxis Precision Medicines presently has a consensus price target of $85.56, suggesting a potential upside of 57.59%. Abeona Therapeutics has a consensus price target of $19.50, suggesting a potential upside of 251.99%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Praxis Precision Medicines 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.75Abeona Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do insiders and institutionals have more ownership in PRAX or ABEO? 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 6.9% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryAbeona Therapeutics beats Praxis Precision Medicines on 9 of the 15 factors compared between the two stocks. Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$269.21M$3.35B$6.10B$10.55BDividend YieldN/A2.28%5.69%4.75%P/E Ratio7.9121.5785.6027.60Price / Sales81.17273.73538.21205.12Price / CashN/A47.1237.9261.55Price / Book5.4910.1413.246.76Net Income-$63.73M-$52.31M$3.30B$275.88M7 Day Performance4.14%5.14%4.35%2.81%1 Month Performance-18.89%14.68%9.51%9.24%1 Year Performance-16.57%30.98%88.04%35.42% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics4.342 of 5 stars$5.54+5.5%$19.50+252.0%-15.2%$269.21M$3.50M7.9190News CoverageAnalyst ForecastPRAXPraxis Precision Medicines2.2534 of 5 stars$52.38-0.1%$85.56+63.3%-16.2%$1.10B$8.55M-4.26110Analyst ForecastNUVBNuvation Bio2.7546 of 5 stars$3.22+0.6%$7.50+132.9%+66.8%$1.10B$7.87M-5.1160Analyst ForecastCOLLCollegium Pharmaceutical4.1521 of 5 stars$34.57+0.5%$42.33+22.5%-12.9%$1.08B$631.45M33.24210News CoveragePositive NewsAnalyst ForecastWVEWAVE Life Sciences4.4741 of 5 stars$7.13+4.9%$20.33+185.2%-8.1%$1.08B$108.30M-7.92240Analyst ForecastORICOric Pharmaceuticals4.1601 of 5 stars$11.62+4.5%$17.29+48.8%+50.5%$1.08BN/A-6.1580News CoverageAnalyst ForecastInsider TradeTRVITrevi Therapeutics2.4807 of 5 stars$8.95+2.1%$21.75+143.0%+211.7%$1.07BN/A-21.3120Analyst ForecastPGENPrecigen4.4247 of 5 stars$3.63+3.4%$8.25+127.3%+276.3%$1.05B$3.92M-8.64190Analyst ForecastGap UpIMNMImmunome1.4134 of 5 stars$11.34-2.2%$23.20+104.6%+8.6%$1.01B$9.04M-3.6840Analyst ForecastGap UpCRONCronos Group1.0741 of 5 stars$2.97+12.9%N/A+23.5%$1.01B$117.61M59.40450Analyst ForecastHigh Trading VolumeBGMBGM Group0.2453 of 5 stars$9.61-5.4%N/A+34.4%$987.78M$25.10M0.00298News CoveragePositive NewsAnalyst ForecastGap Down Related Companies and Tools Related Companies Praxis Precision Medicines Alternatives Nuvation Bio Alternatives Collegium Pharmaceutical Alternatives WAVE Life Sciences Alternatives Oric Pharmaceuticals Alternatives Trevi Therapeutics Alternatives Precigen Alternatives Immunome Alternatives Cronos Group Alternatives BGM Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABEO) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
